Clinical Trials
12 trialsNCT03976323 2026-02-25
Study of Pembrolizumab With Maintenance Olaparib or Maintenance Pemetrexed in First-line (1L) Metastatic Nonsquamous Non-Small-Cell Lung Cancer (NSCLC) (MK-7339-006, KEYLYNK-006)
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT03829319 2026-02-05
LEAP-006
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT03396445 2025-11-05
MK-5890-001
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT02964013 2025-10-14
KEYVIBE-001
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT04716933 2025-09-09
LEAP-006
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT04153565 2025-07-17
MK-3475-A17
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT03631784 2025-03-25
KEYNOTE-799
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT04956692 2024-12-03
MK-3475-A86
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting
NCT03664024 2024-08-22
KEYNOTE-782
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT03950674 2024-06-10
MK-3475-189
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT03850444 2023-09-18
Keynote 042
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT03348904 2019-06-13
Nivolumab and Epacadostat With Platinum Doublet Chemotherapy Versus Platinum Doublet Chemotherapy in Non-Small Cell Lung Cancer
Incyte Corporation
Phase 3 Terminated